<div id="pf31" class="pf w21 h0" data-page-no="31"><div class="pc pc31 w21 h0"><img class="bi x68 y199 w22 h31" alt="" src="data:image/png;base64,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"/><div class="t m0 x13 h2d y19a ffe fse fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x14 h32 y19b ffe fsf fc0 sc0 ls1 ws1">®</div><div class="t m0 x61 h2d y19a ffe fse fc0 sc0 ls1 ws1">_comp_rev<span class="_ _6"></span>_V7_VP </div><div class="t m0 x13 h24 y1a2 fff fsa fc0 sc0 ls1 ws1">IDENTIFICAÇÃO DO <span class="_ _0"></span>MEDICAM<span class="_ _0"></span>ENTO<span class="_ _0"></span> </div><div class="t m0 x69 h24 y1a3 fff fsa fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x20 h36 y1a4 fff fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x6a h27 y1a3 ffe fsa fc0 sc0 ls1 ws1"> </div><div class="t m0 x2e h27 y1a5 ffe fsa fc9 sc0 ls1 ws1">(<span class="fc0">bissulfato de clop<span class="_ _0"></span>idogrel</span>) </div><div class="t m0 x6b h27 y1a6 ffe fsa fc0 sc0 ls1 ws1">MEDICAMENTO <span class="_ _0"></span>SIMILAR EQUIVALENT<span class="_ _0"></span>E AO MEDI<span class="_ _0"></span>CAMENT<span class="_ _0"></span>O DE REFERÊNCI<span class="_ _0"></span>A </div><div class="t m0 x13 h24 y1a7 fff fsa fc0 sc0 ls1 ws1">APRESENTAÇÃO<span class="_ _0"></span> </div><div class="t m0 x13 h27 y1a8 ffe fsa fc9 sc0 ls1 ws1">Comprimido revestido<span class="_ _0"></span> 75 mg: <span class="_ _0"></span>embalagens com 10 ou 30<span class="_ _0"></span> comprimidos revestido<span class="_ _0"></span>s.<span class="_ _0"></span> </div><div class="t m0 x13 h24 y1a9 fff fsa fc0 sc0 ls1 ws1">USO ORAL </div><div class="t m0 x13 h24 y1aa fff fsa fc0 sc0 ls1 ws1">USO ADULTO<span class="_ _0"></span><span class="ffe"> </span></div><div class="t m0 x13 h24 y1ab fff fsa fc0 sc0 ls1 ws1">COMPOSIÇÃO<span class="_ _0"></span> </div><div class="t m0 x13 h27 y1ac ffe fsa fc0 sc0 ls1 ws1">Cada co<span class="_ _0"></span>mprimido revestido contém:<span class="_ _0"></span> </div><div class="t m0 x13 h27 y1ad ffe fsa fc0 sc0 ls1 ws1">bissulfato de clopid<span class="_ _0"></span>ogrel* .............<span class="_ _0"></span>................................................................................................ 97,88 mg<span class="_ _6a"></span> </div><div class="t m0 x13 h27 y1ae ffe fsa fc0 sc0 ls1 ws1">excipientes ** q.s.p. .<span class="_ _0"></span>..............................................<span class="_ _0"></span>......................................................<span class="_ _6a"></span>.......... 1 comprimido </div><div class="t m0 x13 h27 y1af ffe fsa fc0 sc0 ls1 ws1">* Equivalente à 75<span class="_ _0"></span> mg de clopidogrel base.</div><div class="t m0 x13 h27 y1b0 ffe fsa fc0 sc0 ls1 ws1">**Excipientes: macrogol, <span class="_ _0"></span>manitol, celulose <span class="_ _0"></span>microcristalina, hiprolo<span class="_ _0"></span>se, óleo vegetal hidrogenado<span class="_ _0"></span> e opadry II branco.<span class="_ _6b"></span> </div><div class="t m0 x13 h24 y1b1 fff fsa fc0 sc0 ls1 ws1">INFORMAÇÕ<span class="_ _0"></span>ES AO PACIENT<span class="_ _0"></span>E<span class="ffe"> </span></div><div class="t m0 x13 h24 y1b2 fff fsa fc0 sc0 ls1 ws1">1. PARA QUE ESTE M<span class="_ _0"></span>EDICAM<span class="_ _0"></span>ENTO É INDICADO?</div><div class="t m0 x13 h27 y1b3 ffe fsa fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x61 h37 y1b4 ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x6c h27 y1b3 ffe fsa fc0 sc0 ls1 ws1"> (bissu<span class="_ _6"></span>lfato de clopidogrel) é <span class="_ _6"></span>indicado para <span class="_ _6"></span>a <span class="_ _6"></span>prevenção secundár<span class="_ _0"></span>ia (após <span class="_ _6"></span>a ocorrência) dos <span class="_ _6"></span>eventos aterotrombóticos, </div><div class="t m0 x13 h27 y1b5 ffe fsa fc0 sc0 ls1 ws1">como <span class="_ _0"></span>po<span class="_ _0"></span>r <span class="_ _0"></span>exe<span class="_ _0"></span>mplo, <span class="_ _10"></span>infarto <span class="_ _10"></span>agudo <span class="_ _10"></span>do <span class="_ _10"></span>miocárdio <span class="_ _10"></span>(IM) <span class="_ _10"></span>(infarto<span class="_ _0"></span> <span class="_ _0"></span>d<span class="_ _0"></span>o <span class="_ _10"></span>coração), <span class="_ _10"></span>acidente <span class="_ _10"></span>vascular <span class="_ _10"></span>cerebral <span class="_ _10"></span>(AVC) <span class="_ _10"></span>(derra<span class="_ _0"></span>me) <span class="_ _0"></span>e<span class="_ _0"></span> </div><div class="t m0 x13 h27 y1b6 ffe fsa fc0 sc0 ls1 ws1">morte <span class="_ _6a"></span>vascular <span class="_ _6a"></span>em <span class="_ _6a"></span>pacientes <span class="_ _6c"></span>adultos <span class="_ _6a"></span>q<span class="_ _0"></span>ue <span class="_ _6a"></span>apresentaram <span class="_ _6a"></span>IM<span class="_ _0"></span> <span class="_ _6a"></span>ou <span class="_ _6a"></span>AVC <span class="_ _6a"></span>recente <span class="_ _6a"></span>ou <span class="_ _6a"></span>uma <span class="_ _6a"></span>co<span class="_ _0"></span>ndição <span class="_ _6a"></span>conhecida <span class="_ _6a"></span>co<span class="_ _0"></span>mo <span class="_ _6a"></span>doença </div><div class="t m0 x13 h28 y1b7 ffe fsa fc0 sc0 ls1 ws1">arterial periférica<span class="_ _0"></span> (doença nos vasos san<span class="_ _0"></span>guíneos dos <span class="_ _0"></span>membros)<span class="_ _0"></span>.<span class="fff fsc"> </span></div><div class="t m0 x13 h27 y1b8 ffe fsa fc0 sc0 ls1 ws1">Síndrome Coronária <span class="_ _0"></span>Aguda: <span class="_ _0"></span>nos p<span class="_ _0"></span>acientes co<span class="_ _0"></span>m Síndrome C<span class="_ _0"></span>oronária <span class="_ _0"></span>Aguda (SCA) [<span class="_ _0"></span>angina instável <span class="_ _0"></span>(tipo <span class="_ _0"></span>severo de <span class="_ _0"></span>dor no </div><div class="t m0 x13 h27 y1b9 ffe fsa fc0 sc0 ls1 ws1">peito) ou <span class="_ _6"></span>IM], incluindo <span class="_ _6"></span>tanto aqueles <span class="_ _6"></span>controlados clinicamente, quanto os <span class="_ _7"></span>s<span class="_ _0"></span>ubmetidos à Intervenção C<span class="_ _6"></span>oronária Percutânea </div><div class="t m0 x13 h27 y1ba ffe fsa fc0 sc0 ls1 ws1">com ou sem colocação<span class="_ _0"></span> de <span class="_ _0"></span><span class="ff11">stent</span> (prótese nas artérias do<span class="_ _0"></span> coração).   <span class="_ _0"></span> </div><div class="t m0 x13 h24 y1bb fff fsa fc0 sc0 ls1 ws1">Fibrilação Atria<span class="_ _0"></span>l  </div><div class="t m0 x13 h27 y1bc ffe fsa fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x61 h37 y1bd ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x6c h27 y1bc ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _0"></span>(bissulfato de <span class="_ _0"></span>clo<span class="_ _0"></span>pidogrel<span class="ls11">) <span class="_ _0"></span></span>é <span class="_ _0"></span>indicado <span class="_ _0"></span>em ad<span class="_ _0"></span>ultos par<span class="_ _0"></span>a <span class="_ _0"></span>a <span class="_ _0"></span>prevenção <span class="_ _0"></span>de <span class="_ _0"></span>eventos ater<span class="_ _0"></span>otrombóticos <span class="_ _0"></span>e <span class="_ _0"></span>tromboembólicos </div><div class="t m0 x13 h27 y1be ffe fsa fc0 sc0 ls1 ws1">(quadros <span class="_ _7"></span>esp<span class="_ _0"></span>ecíficos <span class="_ _7"></span>caracteriz<span class="_ _0"></span>ados <span class="_ _6"></span>pela <span class="_ _7"></span>formação <span class="_ _7"></span>de um <span class="_ _5"></span>co<span class="_ _0"></span>águlo <span class="_ _7"></span>de <span class="_ _6"></span>sangue <span class="_ _7"></span>no <span class="_ _6"></span>interior <span class="_ _7"></span>de <span class="_ _6"></span>um <span class="_ _7"></span>vaso <span class="_ _6"></span>sanguíneo) <span class="_ _7"></span>em <span class="_ _6"></span>pacientes </div><div class="t m0 x13 h27 y1bf ffe fsa fc0 sc0 ls1 ws1">com <span class="_ _6a"></span>fibrilação <span class="_ _6a"></span>atrial <span class="_ _6b"></span>(F<span class="_ _0"></span>A) <span class="_ _6a"></span>(tipo <span class="_ _6a"></span>de <span class="_ _6b"></span>arritmia <span class="_ _6a"></span>onde <span class="_ _6c"></span>há <span class="_ _6a"></span>batimentos <span class="_ _6b"></span>r<span class="_ _0"></span>ápidos <span class="_ _6a"></span>e <span class="_ _6a"></span>desordenados <span class="_ _6a"></span>do <span class="_ _6a"></span>coração) <span class="_ _6b"></span>que <span class="_ _6a"></span>possuem <span class="_ _6a"></span>pelo </div><div class="t m0 x13 h27 y1c0 ffe fsa fc0 sc0 ls1 ws1">menos <span class="_ _6b"></span>um <span class="_ _6b"></span>fator <span class="_ _6b"></span>de <span class="_ _6a"></span>risco <span class="_ _6b"></span>para <span class="_ _6b"></span>a <span class="_ _6b"></span>ocorrência <span class="_ _6a"></span>de <span class="_ _6b"></span>eventos <span class="_ _10"></span>vasc<span class="_ _0"></span>ulares <span class="_ _6b"></span>(por <span class="_ _6a"></span>exemplo, <span class="_ _10"></span>der<span class="_ _0"></span>rame, <span class="_ _6b"></span>infarto <span class="_ _6b"></span>do <span class="_ _6b"></span>co<span class="_ _0"></span>ração) <span class="_ _6b"></span>e <span class="_ _6b"></span>que <span class="_ _6b"></span>não </div><div class="t m0 x13 h38 y1c1 ff12 fsa fc0 sc0 ls1 ws1">podem <span class="_ _10"></span>fazer <span class="_ _10"></span>u<span class="_ _0"></span>so <span class="_ _10"></span>do <span class="_ _6b"></span>tratamento <span class="_ _10"></span>com <span class="_ _10"></span>medica<span class="_ _0"></span>mentos <span class="_ _10"></span>co<span class="_ _0"></span>nhecidos <span class="_ _10"></span>co<span class="_ _0"></span>mo <span class="_ _10"></span>“antagonis<span class="_ _10"></span>tas <span class="_ _10"></span>da <span class="_ _6b"></span>vita<span class="_ _0"></span>mina <span class="_ _0"></span>K” <span class="_ _6b"></span>(AVK) <span class="_ _10"></span>(<span class="_ _0"></span>ex. <span class="_ _10"></span>risco <span class="_ _6b"></span>de </div><div class="t m0 x13 h27 y1c2 ffe fsa fc0 sc0 ls1 ws1">sangramento ou avaliação<span class="_ _0"></span> médica que co<span class="_ _0"></span>ncluiu que o uso de AVK é i<span class="_ _0"></span>napropriad<span class="_ _0"></span>o). <span class="_ _0"></span> </div><div class="t m0 x13 h27 y1c3 ffe fsa fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x61 h37 y1c4 ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x6c h27 y1c3 ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _0"></span>(bissulfato <span class="_ _10"></span>de <span class="_ _10"></span>clopidogrel<span class="_ _0"></span><span class="ls11">) <span class="_ _0"></span></span>é <span class="_ _10"></span>indicad<span class="_ _0"></span>o <span class="_ _0"></span>em <span class="_ _0"></span>co<span class="_ _0"></span>mbinação <span class="_ _10"></span>com <span class="_ _0"></span>o <span class="_ _10"></span>ácid<span class="_ _0"></span>o <span class="_ _10"></span>acetilsalicílico <span class="_ _10"></span>(AAS) <span class="_ _0"></span>na <span class="_ _10"></span>prevenção <span class="_ _10"></span>de <span class="_ _10"></span>eventos </div><div class="t m0 x13 h27 y1c5 ffe fsa fc0 sc0 ls1 ws1">aterotrombóticos <span class="_ _10"></span>e <span class="_ _6b"></span>tro<span class="_ _0"></span>mboembólicos, <span class="_ _10"></span>incluindo <span class="_ _6b"></span>derra<span class="_ _0"></span>me <span class="_ _0"></span>ce<span class="_ _0"></span>rebral.<span class="_ _0"></span> <span class="_ _6b"></span>Plaq</div><div class="t m0 x6d h37 y1c6 ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x34 h27 y1c5 ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _10"></span>(bissulfato <span class="_ _10"></span>d<span class="_ _0"></span>e <span class="_ _10"></span>clo<span class="_ _0"></span>pidogrel<span class="ls11">) <span class="_ _6b"></span></span>em <span class="_ _0"></span>co<span class="_ _0"></span>mbinação <span class="_ _10"></span>co<span class="_ _0"></span>m </div><div class="t m0 x13 h27 y1c7 ffe fsa fc0 sc0 ls1 ws1">AAS <span class="_ _6b"></span>de<span class="_ _0"></span>monstrou <span class="_ _6b"></span>reduzir <span class="_ _6a"></span>a <span class="_ _6b"></span>taxa <span class="_ _6b"></span>d<span class="_ _0"></span>e <span class="_ _6b"></span>der<span class="_ _0"></span>rame <span class="_ _6b"></span>cerebral,<span class="_ _0"></span> <span class="_ _6b"></span>infarto <span class="_ _6a"></span>do <span class="_ _6b"></span>coração, <span class="_ _6b"></span>embolismo <span class="_ _6a"></span>sistêmico <span class="_ _6a"></span>fora <span class="_ _6b"></span>do <span class="_ _6a"></span>sistema <span class="_ _6b"></span>nervoso </div><div class="t m0 x13 h27 y1c8 ffe fsa fc0 sc0 ls1 ws1">central (obstrução de <span class="_ _0"></span>um vaso ou artéria d<span class="_ _0"></span>o <span class="_ _0"></span>corpo que não sej<span class="_ _0"></span>a no sistema nervoso central), <span class="_ _0"></span>ou morte vascular.<span class="_ _10"></span> </div><div class="t m0 x13 h24 y1c9 fff fsa fc0 sc0 ls1 ws1">2. COMO<span class="_ _0"></span> ESTE MEDICAM<span class="_ _0"></span>ENTO FUNCIONA?</div><div class="t m0 x13 h27 y1ca ffe fsa fc0 sc0 ls1 ws1">Plaq</div><div class="t m0 x61 h37 y1cb ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x6c h27 y1ca ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _6b"></span>(bissulfato <span class="_ _6b"></span>de <span class="_ _6a"></span>clopidogrel<span class="ls11">) <span class="_ _6b"></span></span>é <span class="_ _6a"></span>um <span class="_ _6b"></span>medicamento <span class="_ _6b"></span>que<span class="_ _0"></span> <span class="_ _6b"></span>possui <span class="_ _6b"></span>e<span class="_ _0"></span>m <span class="_ _6b"></span>sua <span class="_ _6a"></span>fórmula <span class="_ _6b"></span>uma <span class="_ _6b"></span>sub<span class="_ _0"></span>stância <span class="_ _6b"></span>chamada <span class="_ _6a"></span>bissulfato <span class="_ _6b"></span>de </div><div class="t m0 x13 h27 y1cc ffe fsa fc0 sc0 ls1 ws1">clopidogrel e p<span class="_ _0"></span>ertence a u<span class="_ _0"></span>m grupo de <span class="_ _0"></span>medicamentos conheci<span class="_ _0"></span>dos co<span class="_ _0"></span>mo anti<span class="_ _0"></span>plaquetário<span class="_ _0"></span>s. As <span class="_ _0"></span>Plaquetas são e<span class="_ _0"></span>struturas <span class="_ _0"></span>muito </div><div class="t m0 x13 h27 y1cd ffe fsa fc0 sc0 ls1 ws1">pequenas <span class="_ _6c"> </span>d<span class="_ _0"></span>o <span class="_ _40"> </span>sangue, <span class="_ _40"> </span>menores <span class="_ _40"> </span>que <span class="_ _40"> </span>as <span class="_ _6c"> </span>cé<span class="_ _0"></span>lulas <span class="_ _40"> </span>sanguíneas <span class="_ _6d"> </span>vermel<span class="_ _0"></span>has <span class="_ _6c"></span>e <span class="_ _40"> </span>branca<span class="_ _0"></span>s, <span class="_ _40"> </span>que <span class="_ _6c"> </span>se <span class="_ _6d"> </span>agrupam <span class="_ _6c"> </span>d<span class="_ _0"></span>urante <span class="_ _40"> </span>a <span class="_ _6c"> </span>co<span class="_ _0"></span>agulação<span class="_ _0"></span> </div><div class="t m0 x13 h27 y1ce ffe fsa fc0 sc0 ls1 ws1">sanguínea. <span class="_ _10"></span>P<span class="_ _0"></span>revenindo <span class="_ _6b"></span>este <span class="_ _10"></span>agrupa<span class="_ _0"></span>mento, <span class="_ _10"></span>o <span class="_ _6b"></span>bissulfato <span class="_ _6b"></span>de <span class="_ _6b"></span>clopidogrel <span class="_ _6b"></span>age <span class="_ _6b"></span>no <span class="_ _10"></span>sangue <span class="_ _10"></span>r<span class="_ _0"></span>eduzindo <span class="_ _6b"></span>a <span class="_ _6b"></span>chance <span class="_ _10"></span>d<span class="_ _0"></span>e <span class="_ _10"></span>formação <span class="_ _6b"></span>de </div><div class="t m0 x13 h27 y1cf ffe fsa fc0 sc0 ls1 ws1">trombos <span class="_ _6d"> </span>(coág<span class="_ _0"></span>ulos  sanguíneos). <span class="_ _6d"> </span>Po<span class="_ _0"></span>r <span class="_ _6d"> </span>isso,  P<span class="_ _0"></span>laq</div><div class="t m0 x6e h37 y1d0 ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x5a h27 y1cf ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _6d"> </span>(bissulfato  de <span class="_ _6d"> </span>clop<span class="_ _0"></span>idogrel<span class="ls11">) <span class="_ _6d"> </span></span>é  prescrito  pelo <span class="_ _6d"> </span>médico  para <span class="_ _6d"> </span>prevenir  a </div><div class="t m0 x13 h27 y1d1 ffe fsa fc0 sc0 ls1 ws1">ocorrência <span class="_ _10"></span>d<span class="_ _0"></span>e <span class="_ _10"></span>IM, <span class="_ _10"></span>acidente <span class="_ _10"></span>vascular <span class="_ _10"></span>cereb<span class="_ _0"></span>ral <span class="_ _10"></span>isquêmico <span class="_ _10"></span>(derra<span class="_ _0"></span>me) <span class="_ _0"></span>o<span class="_ _0"></span>u <span class="_ _10"></span>outras <span class="_ _10"></span>doenças <span class="_ _10"></span>d<span class="_ _0"></span>ecorrentes <span class="_ _10"></span>da <span class="_ _10"></span>obstrução <span class="_ _10"></span>d<span class="_ _0"></span>os <span class="_ _10"></span>vasos </div><div class="t m0 x13 h27 y1d2 ffe fsa fc0 sc0 ls1 ws1">sanguíneos.  </div><div class="t m0 x13 h27 y1d3 ffe fsa fc0 sc0 ls1 ws1">O <span class="_ _7"></span>uso <span class="_ _7"></span>rep<span class="_ _0"></span>etido <span class="_ _7"></span>d<span class="_ _0"></span>e <span class="_ _7"></span>P<span class="_ _0"></span>laq</div><div class="t m0 x6f h37 y1d4 ffe fs13 fc0 sc0 ls1 ws1">®</div><div class="t m0 x21 h27 y1d3 ffe fsa fc0 sc0 ls1 ws1"> <span class="_ _7"></span>(bissulfato <span class="_ _7"></span>de <span class="_ _6"></span>clopidogrel<span class="ls11">) <span class="_ _6"></span><span class="ls1">produz <span class="_ _7"></span>inibição <span class="_ _7"></span>substanc<span class="_ _0"></span>ial <span class="_ _7"></span>na <span class="_ _7"></span>a<span class="_ _0"></span>gregação <span class="_ _6"></span>plaquetária <span class="_ _7"></span>a <span class="_ _6"></span>partir <span class="_ _7"></span>do<span class="_ _0"></span> <span class="_ _7"></span>primeiro </span></span></div><div class="t m0 x13 h27 y1d5 ffe fsa fc0 sc0 ls1 ws1">dia, aumentando progressivamente até atingir o estado de equilíbrio entre o terceiro e o s<span class="_ _6"></span>étimo dia de tratamento. Uma vez </div><div class="t m0 x13 h27 y1d6 ffe fsa fc0 sc0 ls1 ws1">descontinuado <span class="_ _6d"> </span>o  tratam<span class="_ _6"></span>ento,  a <span class="_ _40"> </span>agregação  plaquetária <span class="_ _6d"> </span>e <span class="_ _6d"> </span>o<span class="_ _0"></span> <span class="_ _40"> </span>te<span class="_ _0"></span>mpo <span class="_ _6d"> </span>de <span class="_ _6d"> </span>sangramento  retornam<span class="_ _6"></span> <span class="_ _6d"> </span>gradualme<span class="_ _0"></span>nte <span class="_ _6d"> </span>aos <span class="_ _6d"> </span>v<span class="_ _0"></span>alor<span class="_ _0"></span>es </div><div class="t m0 x13 h27 y1d7 ffe fsa fc0 sc0 ls1 ws1">apresentados antes do iníc<span class="_ _0"></span>io do tratamento dentro <span class="_ _0"></span>de 5 dias, em geral.<span class="_ _10"></span> </div><div class="c x1b y21 w9 h7"><div class="t m0 x8 h8 y22 ff3 fs2 fc2 sc0 ls1 ws1">Página 49 de 106</div></div><div class="c x9 y23 w6 h9"><div class="t m0 x8 h8 y24 ff3 fs2 fc3 sc0 ls1 ws1">Voltar</div></div><div style="position:absolute;left:0px;top:0px;"><audio oncontextmenu="return false;" style="width:320px;height:35px;outline:none;" controls controlsList="nodownload"><source src="Audio/A049.mp3" type="audio/mpeg"></audio></div><a class="l" href="#pf2"><div class="d m1" style="border-style:none;position:absolute;left:747.679500px;bottom:1223.682000px;width:24.860000px;height:13.380000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.500000,0.000000,0.000000,1.500000,0.000000,0.000000]}'></div></div>
